Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Alkermes Cites IL-2 Differentiation As It Moves To Phase III, And Seeks A Partner

Company Touts Nemvaleukin At Investor Day

Executive Summary

Executives pointed to the IL-2 variant drug’s potential for subcutaneous administration as a key differentiator from other IL-2 variant programs.

You may also be interested in...



Sanofi Stays Bullish On Synthorx IL-2 Drug, But It’s Early Days

In an interview, oncology development exec Peter Adamson reiterated the company’s view that THOR-707 is best-in-class, but more data are needed to see where its efficacy stands amid the IL-2 herd.

Alkermes Transitions To Novel R&D Products With Learnings From COVID-19

Built on established products and royalties from drug delivery technology, Alkermes is getting ready to launch its first novel product. Scrip talked to CEO Richard Pops about the preparations.

Aadi Starts Small With Fyarro, But Has Tumor-Agnostic Strategy In Mind

The approval of Fyarro marks the first for advanced malignant PEComa, a rare cancer that affects only 100-300 people in the US; it's also the first launch for Aadi Biosciences.

Topics

Related Companies

UsernamePublicRestriction

Register

SC144090

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel